Cassava Sciences Inc vs Nokia Corp — how do they compare? Cassava Sciences Inc trades at $0.93 (market cap $47.75M), while Nokia Corp trades at $10.29 (market cap $53.00B). The key difference: Nokia Corp is far larger — about 1109.9× Cassava Sciences Inc's market cap, and Nokia Corp pays a 1.73% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | NOK | |
|---|---|---|
Market Cap | $47.75M | $53.00B |
Sector | Health | Technology |
52-Week High | $4.64 | $16.83 |
52-Week Low | $0.87 | $4.13 |
Enterprise Value | -$34.93M | $50.95B |
Dividend Yield | — | 1.73% |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
Nokia (NOK) trades at $10.315, up 13.1% on the day, reflecting positive momentum. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, revenue was $19.89B in 2025 with a net income margin of 3.47%, while the P/E ratio of 68.07 suggests a premium valuation. Recent earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026. News highlights focus on AI infrastructure growth driving demand.
The outlook is cautiously optimistic, supported by strong analyst buy consensus (59.61%) and AI-driven demand tailwinds. However, risks include competitive pressures in telecom, volatility in cash flows, and the high P/E ratio indicating stretched valuations. Investment appeal hinges on successful execution in AI and cloud segments offsetting traditional market challenges.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →